Premium
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Author(s) -
Samis Jill,
Lee Paul,
Zimmerman Donald,
Arceci Robert J.,
Suttorp Meinolf,
Hijiya Nobuko
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26028
Subject(s) - medicine , chronic myelogenous leukemia , tyrosine kinase inhibitor , endocrine system , life expectancy , leukemia , pediatrics , tyrosine kinase , population , oncology , cancer , hormone , receptor , environmental health
Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long‐term consequences that differ from adults. Children may develop endocrinopathies related to “off‐target” effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long‐term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.